Panitumumab with Chemo: Continuous or Intermittent for Advanced CRC
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial compares giving panitumumab plus FOLFIRI (two chemotherapy drugs) either continuously or with breaks, as a first treatment for left-sided colorectal cancer that has spread. It's for people whose tumors have certain genetic markers (RAS/BRAF wild-type) and haven't had treatments for advanced disease before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer on the left side (descending colon, sigmoid colon, or rectum) that has spread to other organs and cannot be removed by surgery.
- Your tumor has been tested and is RAS/BRAF wild-type (no mutations in those genes) and is pMMR/MSS (a sign of stable DNA repair).
- You have not had any prior chemotherapy, radiation, or surgery for metastatic colorectal cancer (though surgery to remove the primary tumor is okay).
- You are generally healthy enough for daily activities (ECOG performance status 0 or 1) and have adequate blood counts, liver, and kidney function.
- You are 18 years or older and willing to use effective contraception if sexually active.
- No history of cancer within the past 5 years (except certain skin cancers or cervical cancer in situ), no brain metastases, and no severe lung or eye problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares giving the targeted drug cetuximab continuously vs. intermittently, alongside standard chemotherapy, for people with advanced colorectal cancer whose tumors are RAS/BRAF wild-type. It aims to see if taking breaks from cetuximab works just as well while reducing side effects.
This trial tests whether adding a targeted drug called panitumumab to standard chemotherapy can help people with a certain type of pancreatic cancer that has spread. It is for patients whose tumors do not have a KRAS mutation and who have already had one line of chemotherapy.
This Phase 2 trial compares two treatment combinations as a first treatment for metastatic (spread) colon or rectal cancer. It looks to see whether one combo works better or is safer than the other.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial compares a standard chemotherapy combination (mFOLFOX6) plus a targeted drug (bevacizumab) with or without an immunotherapy (PD-1 antibody) for locally advanced colorectal cancer. It aims to see if adding the immunotherapy improves outcomes for patients with a specific tumor type (pMMR/MSS).
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
Hear when a new Colorectal Cancer Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.